Abstract:Objectives: Interleukin (IL)-25, IL-33, and thymic stromal lymphopoietin (TSLP) are the important drivers for excessive type-2 immunity. It has been well elucidated that IL-25/IL-33/TSLP plays an important role in allergic airway inflammation and remodeling, whereas their roles in idiopathic pulmonary fibrosis (IPF) still remained largely unclear. Herein, the aim of the review is to discuss the potential role and mechanism of IL-25/IL-33/TSLP on IPF by literature analysis and summary. Data source: We have done a literature search using the following terms: ("idiopathic pulmonary fibrosis" OR "IPF" OR "lung fibrosis") and (TSLP or "thymic stromal lymphopoietin" or IL-25 OR IL-17E OR IL-33) from the database of PubMed published in English up to July 2018. Study selection: We have totally found 58 articles by using the retrieval terms mentioned above. By careful title and abstract reading, 10 original research articles of high quality were enrolled for the full text reading and analysis. Two additional relevant studies were also included during the course of literature readings. Results: IL-25/IL-33/TSLP and their corresponding receptors, that is, IL-17BR/ST2L/TSLPR, are shown to be up-regulated both in IPF patients and bleomycin (BLM)-induced lung fibrosis mice model. IL-25 may promote lung fibrosis by activating IL-17BR+fibroblast and IL-17BR+ILC2 (type 2 innate lymphoid cell). Full length (fl)-IL-33, as a transcription factor mainly in the cell nucleus, mediated non-atopic lung inflammation and fibrosis by modulating expressions of several pro-fibrotic mediators, including transforming growth factor (TGF)-b1. By contrast, mature (m)-IL-33 potentiates lung fibrosis by recruiting ST2L+M2 macrophages and ST2L+ILC2 to enlarge type 2 immunity. TSLP was shown to directly promote CCL2 expression in primary human lung fibroblasts (pHLFs). Conclusion: IL-25/IL-33/TSLP contributes to non-allergic lung fibrosis by mediating persistent abnormal epithelial-mesenchymal crosstalk. IL-25/IL-33/TSLP may serve the promising novel target for the treatment of IPF.

Research progress of interleukin-11 in idiopathic pulmonary fibrosis

Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis

Abnormal expression of IGF-binding proteins, an initiating event in idiopathic pulmonary fibrosis?

Expression of interleukin-11 and its receptor in lung of mice with idiopathic pulmonary fibrosis

Role of interleukins in the pathogenesis of pulmonary fibrosis

Interleukin-11 signaling underlies fibrosis, parenchymal dysfunction, and chronic inflammation of the airway

The potential role of interleukin (IL)-25/IL-33/thymic stromal lymphopoietin (TSLP) on the pathogenesis of idiopathic pulmonary fibrosis

Research Advances of IL-22 in Development of Pulmonary Fibrosis

Protective function of interleukin‐22 in pulmonary fibrosis

The Influence of IL-11 on Cardiac Fibrosis in Experimental Models: A Systematic Review

Targeting IL‐11 to reduce fibrocyte circulation and lung accumulation in animal models of pulmonary hypertension‐associated lung fibrosis

Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge

IL-10/IL-10 Receptor 1 Pathway Promotes the Viability and Collagen Synthesis of Pulmonary Fibroblasts Originated from Interstitial Pneumonia Tissues.

Emerging roles for IL-11 in inflammatory diseases

Exploring therapeutic targets for molecular therapy of idiopathic pulmonary fibrosis

Interleukin-19 Aggravates Pulmonary Fibrosis via Activating Fibroblast through TGF-β/Smad Pathway

The effect of hepatic stellate cell derived-IL-11 on hepatocyte injury in hepatic fibrosis

Research on CXCL12/CXCR4 biological axis and idiopathic pulmonary fibrosis

Neutralization of interleukin-11 attenuates silica particles-induced pulmonary inflammation and fibrosis in vivo

Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis

Research progress of idiopathic pulmonary fibrosis and its treatment